Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18174 ↗Kurz gefasst
Editorial in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Chan Xie. Beteiligte Einrichtung: Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Antiviral Agents. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
LINKED CONTENT This article is linked to Chen et al papers. To view these articles, visit https://doi.org/10.1111/apt.18131 and https://doi.org/10.1111/apt.18142
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Chan Xie
Zitieren
APA
Xie, C. (2024). Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18174
Vancouver
Xie C. Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18174
BibTeX
@article{Xie2024,
author = {Xie, Chan},
title = {Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV ‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18174}
}
EUVIMED